Who Wrote the Standard?谁写下了这个标准誰寫下了這個標準 · 04
Reviewed Is Not the Same as Answered
审查通过,不等于这题答过
審查通過,不等於這題答過
A reliable conclusion can be sent to answer a question it never addressed. Compare scopes, not intentions.
一份结论可以很可靠,却被送去回答它从未处理的问题。要比的不是态度,而是范围。
一份結論可以很可靠,卻被送去回答它從未處理的問題。要比的不是態度,而是範圍。
In 1972, Alvin Weinberg described questions expressible scientifically but practically resistant to direct experimental answers. His low-dose radiation example, under its stipulated conditions, would require roughly eight billion mice to identify a tiny change. The point is the distance between posing a question and completing its answer.
The source constructs a separate handover: imagine well-reviewed high-dose experiments whose conclusions remain within tested doses. A question about choosing a low-dose extrapolation model receives science has reviewed it. This is not Weinberg's recorded case or a judgment about actual radiation standards.
A review can be reliable while its conclusion is assigned a question it never answered. The inquiry concerns questions, records, and consequences rather than an invented lack of scientific honesty.
Several scopes differ. Authorization may be broad; actual work narrower; an adopter's consequences broader again. Reviewed cannot compress them into one undifferentiated approval. Each needs its own record.
Permission to examine something does not establish its examination on this occasion. Encountering an unauthorized issue does not create authority either. Exceeding authority in review differs from someone else's enlarged use of a conclusion.
Completion of procedure does not establish substantive response. Submission, voting, and filing can be real while a particular allocation of risk remains unexamined. This respects procedural evidence without making its certificate prove everything.
Limited scope is ordinary and often necessary for careful work. The problem is recording an outside matter as resolved within a conclusion. A narrow review is not automatically an improper one, and a conclusion cannot certify every future use.
Evidence assessment may legitimately include values, such as different costs of error. Its name alone establishes neither their absence nor complete treatment of every normative premise. The specific choice on this occasion matters.
Calculating under a threshold differs from questioning its origin. Correct statistical work can answer the first without addressing the second. Fluency in calculation can make the distinction easier, not harder, to overlook.
Examination can identify the actual question, the submitted task, authorization, processing record, stated limits, and assigned consequence. These are locating tools, not a grading scale for disciplines. A clear record may establish a sound connection as well as a mismatch.
The source calls one mismatch misrouting: an unaddressed challenge, or one outside a conclusion's own scope, is registered as answered. Mentioning the same subject is not enough. The challenged matter must actually have entered the work.
Misrouting can move forward when a submitter enlarges a limited conclusion, or backward when a recipient sends a challenge to an earlier review that never addressed it. Different handovers identify different positions to question.
A response retaining the premise is not misrouting merely because the challenger dislikes it. Relevant alternatives may have been considered and rejected. Being answered and winning cannot be identical without making completion impossible.
Using a conclusion beyond its evidential scope is a broader phenomenon. Using research to make a policy judgment need not claim that research has eliminated every question about that choice. The source preserves that distinction.
No villain is required. Reviewers follow authorization, adopters follow approval rules, and responders close already-reviewed matters. Every step can have a reason while the initial question remains untouched throughout the chain.
Searching only for concealed motives can miss those handover rules. Deliberate advocacy disguised as science is another possible mechanism requiring evidence. It can coexist without being necessary to every mismatch of scope.
Expanding authorization is an obvious response and may help. But if membership still depends on not rejecting the challenged premise, added text has not established independent examination of that premise.
Internal revision can genuinely occur. Its possibility does not establish an address where affected people can require response and initiate review. Change happening and an available means of questioning need separate descriptions.
Real rules can state limited scope clearly. ANSI's Board of Standards Review says it does not evaluate content or hear technical-content appeals, while it can examine whether technical concerns received due process. That boundary is not itself evidence of misrouting.
A later use of procedural approval to close a substantive challenge would require that handover's record. The source found no such case there and retains a possible setting, not an invented finding. A useful illustration cannot supply missing evidence.
GRADE should not be casually cast as an example of misrouting, either. Its 2013 handbook places selection and ranking of patient-important outcomes before evidence grading. This does not settle participation or review arrangements, but the choice has not simply been omitted.
Whether low-risk-of-bias findings close an outcome-choice challenge requires actual citation and handling records. Whether approved statistical analysis certifies a threshold's suitability requires the same. Possibility is not occurrence.
The source proposes a mechanism for testing: closure accepts only evidence-review conclusions while effective routes elsewhere exclude normative questions. Together they could let an unexplained choice continue as apparently pure technique.
Both conditions matter. Another competent route changes the pattern; other grounds for closure change it too. The source found no rule set in its search establishing both. The proposed mechanism remains to be demonstrated.
Not finding a case establishes neither rarity nor ubiquity. It marks the material's present limit. A method demanding accurate proof boundaries cannot promote possible into established on its own behalf.
The object remains particular: this challenge, task, power, record, qualification, and closure. Their comparison may reveal an unintended stable mismatch or show that the question was actually addressed. The method must permit either result.
No radiation model, statistical threshold, or medical outcome is prescribed here. Different questions need their own entrances. Evidence quality can be assessed seriously while reasons for choices need not disguise themselves as arithmetic errors to be heard.
This distinction can also protect the reviewer. A team that carefully examined a specified experiment should not inherit a claim to have settled every later policy use. Recording the remaining question keeps its achievement and its unfinished surroundings visible together.
The approval stamp can keep the weight it really earned. An unanswered matter can remain beside it. Returning a conclusion to its scope does not weaken science. It prevents issuing a certificate of completion for a judgment not yet completed.
1972年,阿尔文·温伯格谈到一类可以用科学语言提出,却在实际条件下难以由直接实验回答的问题。他举低剂量辐射的例子,按文中所设条件,要辨认很小的变化,所需小鼠竟约八十亿只。数字的意义不在吓人,而在说明可提出与可完成回答之间有距离。
原论文借这道距离,另构造一段交接:设高剂量实验已经认真审过,结论只到实验所及范围。有人问低剂量外推模型为何这样选,却得到科学已经审过的答复。这不是温伯格记载的真实案件,更不是本文对现实辐射标准的判断。
这一示意让问题变得清楚:审查可能完全可靠,结论却被派去回答它没答过的题。要查的不是科学家是否诚实,而是问题、处理记录与被赋予的后果,有没有对上。
一项审查至少有几种不同的范围。它获准审什么,文件里可以写得很宽;它实际审了什么,记录可能较窄;采用者随后给它什么效力,又可能更宽。不能把这几种范围压成审过两字。
获准做某件事,不证明这一次已经做过。反过来,实际碰到授权外的问题,也不因碰到了便取得权限。审查本身是否越权,与后来有人扩大使用结论,是两个需要分别核的动作。
通过程序,也不能单独证明实质答过。一个标准按规提交、表决和归档,能够证明这些程序发生过;它是否处理了某项风险取舍,仍要看报告。这不是轻视程序,而是不把程序证书派去承担全部证明。
范围有限本身没有错。专业工作常常必须划窄,才能做得扎实。问题发生在范围外的东西,被记录为已在这项结论里得到解决;有限不等于冒领,结论不该替自己的用途自动担保。
证据审查也不一律只碰事实。判证据够不够,可能已经考虑错判的代价。不能看到证据二字就假定没有价值;也不能说专家考虑过价值,便认定所有规范前提都已审完。要落到这一次是哪一项。
问怎样按门槛计算,与问门槛从哪里来,不是同一道题。统计方法无误,可以是对前者的好回答;若被用来结束后者,就还欠着来源、替代和修改的讨论。计算越熟练,这个区别反而越容易被省掉。
核对时,可以先写清本次真正问的是什么,再找交审任务是否包含它,谁有权限,记录处理到了哪里,结论自己承诺哪些条件,最后被用作什么后果。它是一组寻址的工具,不是一张给学科评分的量表。
原论文把一种后果称为错送:没有处理这一质疑,或者结论自己说的范围不够,却把质疑登记为已经回答。所谓已经回答,不只是有人提过同一个词,而是那件事真的进入了处理。
错送可以往两个方向发生。交件者把有限审查的结论向前扩大,说前提已得到确认;接件者收到质疑,把它往回推到先前没处理这题的审查,以此结案。方向不同,应该找的责任地址也不同。
但已经答到而决定保留,不能只因提问者不满意便叫错送。对方可能解释了为什么不取替代方案,也可能按现有材料维持原判。答没答与答得合不合我意,必须分开,否则审查永远无法完成。
结论被用到证明范围之外,原论文另称转用。不是所有转用都等于宣布质疑已经解决。把某种研究结果拿去作政策判断,与说研究已经消除了对那项选择的全部问题,需要留下区别。
这样的错位不需要坏人。审查者认真按授权工作,采用者遵循通过即可采用的规定,答复者依惯例将已审事项结案。每一步都有来由,最初那项问题却可能一路没有被处理。
若只找隐藏动机,就可能漏掉这些交接规则。有人确实可能借科学推动立场,那是另一个需要证据的机制;它可以并存,却不是每次范围错位的必要条件。批评不应先要求编出一个伪装者。
最自然的补法是扩大授权,让证据审查也接规范问题。这可能有用,但若成员资格仍要求不得否定被问的那条前提,新增文字并没有带来相对于前提的独立追问。
内部当然可能自己改写旧做法。这个可能性不应被否认,却也不能证明现在已有一处可以寻址、能要求回应与复审的位置。曾经发生变化,与受影响者有办法启动变化,需要分别说明。
真实规则可以先给范围划清。美国国家标准学会的标准审查委员会说明,它不评价标准内容,也不审技术问题本身的申诉;但可审技术异议是否按适当程序被考虑。这是公开的功能边界,不是本身已经错送的证据。
若后来有人拿程序合规结论,去宣布技术前提的质疑已答,才需要对那次交接查记录。原论文没有找到这一实际结案个案,便只把它留作可能场所。不能为了一个好例子,替没有的证据补齐最后一步。
GRADE也不能被草率拿来当反面。其2013年手册在评证据之前,就要求先考虑哪些患者重要结局应当进入,以及重要程度;它没有把这一取舍简单假装不存在。具体谁参与、有没有足够复审,仍需另查。
因此,一项低偏倚风险评定,是否被用来结束对研究终点选择的质疑,要找实际援引;一篇统计分析通过审稿,是否被用来确认某阈值适用,也要找处理记录。可能发生,不等于已经发生。
原论文还提出一条待证路径:若结案只接收证据审查结论,而规范前提的追问又在别的有效程序中进不去,两边合在一起,便可能让未经说明的取舍继续像纯技术一样运行。
两个条件缺一,不能把故事讲满。别处若有能接的权限,就未必是完全排除;结案若接受别种依据,也不是只能向证据证书借答复。源文在查过的规则中,没有找到同时满足的实例。
这份没有找到很重要。它既不证明错送少见,也不证明无处不在;只说明当前材料到此。一个方法若要求别人承认证明范围,自己便不能把有可能写成已确立。
所以,问的对象始终很具体。哪一质疑,哪份任务,哪项授权,哪段处理,哪句限度,哪次结案。它们能帮助拆开一种稳定却无意的误认,也可能显示这一回其实已经答到了。
这一篇没有裁定某个辐射模型、统计门槛或医学终点应该选哪一个。它保护的是不同问题仍有各自的入口:证据质量继续认真审,取舍理由也不必靠伪装成数据错误,才能进入讨论。
一枚通过印章可以保留,也应该保留它真正证明的重量。旁边还可以写上另一项未答。让结论回到自己的范围,不是削弱科学,而是让它不必替未完成的判断出具一张已经完成的证明。
1972年,阿爾文·溫伯格談到一類可以用科學語言提出,卻在實際條件下難以由直接實驗回答的問題。他舉低劑量輻射的例子,按文中所設條件,要辨認很小的變化,所需小鼠竟約八十億只。數字的意義不在嚇人,而在說明可提出與可完成回答之間有距離。
原論文借這道距離,另構造一段交接:設高劑量實驗已經認真審過,結論只到實驗所及範圍。有人問低劑量外推模型為何這樣選,卻得到科學已經審過的答覆。這不是溫伯格記載的真實案件,更不是本文對現實輻射標準的判斷。
這一示意讓問題變得清楚:審查可能完全可靠,結論卻被派去回答它沒答過的題。要查的不是科學家是否誠實,而是問題、處理記錄與被賦予的後果,有沒有對上。
一項審查至少有幾種不同的範圍。它獲准審什麼,文件裡可以寫得很寬;它實際審了什麼,記錄可能較窄;採用者隨後給它什麼效力,又可能更寬。不能把這幾種範圍壓成審過兩字。
獲准做某件事,不證明這一次已經做過。反過來,實際碰到授權外的問題,也不因碰到了便取得權限。審查本身是否越權,與後來有人擴大使用結論,是兩個需要分別核的動作。
通過程序,也不能單獨證明實質答過。一個標準按規提交、表決和歸檔,能夠證明這些程序發生過;它是否處理了某項風險取捨,仍要看報告。這不是輕視程序,而是不把程序證書派去承擔全部證明。
範圍有限本身沒有錯。專業工作常常必須劃窄,才能做得扎實。問題發生在範圍外的東西,被記錄為已在這項結論裡得到解決;有限不等於冒領,結論不該替自己的用途自動擔保。
證據審查也不一律只碰事實。判證據夠不夠,可能已經考慮錯判的代價。不能看到證據二字就假定沒有價值;也不能說專家考慮過價值,便認定所有規範前提都已審完。要落到這一次是哪一項。
問怎樣按門檻計算,與問門檻從哪裡來,不是同一道題。統計方法無誤,可以是對前者的好回答;若被用來結束後者,就還欠著來源、替代和修改的討論。計算越熟練,這個區別反而越容易被省掉。
核對時,可以先寫清本次真正問的是什麼,再找交審任務是否包含它,誰有權限,記錄處理到了哪裡,結論自己承諾哪些條件,最後被用作什麼後果。它是一組尋址的工具,不是一張給學科評分的量表。
原論文把一種後果稱為錯送:沒有處理這一質疑,或者結論自己說的範圍不夠,卻把質疑登記為已經回答。所謂已經回答,不只是有人提過同一個詞,而是那件事真的進入了處理。
錯送可以往兩個方向發生。交件者把有限審查的結論向前擴大,說前提已得到確認;接件者收到質疑,把它往回推到先前沒處理這題的審查,以此結案。方向不同,應該找的責任地址也不同。
但已經答到而決定保留,不能只因提問者不滿意便叫錯送。對方可能解釋了為什麼不取替代方案,也可能按現有材料維持原判。答沒答與答得合不合我意,必須分開,否則審查永遠無法完成。
結論被用到證明範圍之外,原論文另稱轉用。不是所有轉用都等於宣佈質疑已經解決。把某種研究結果拿去作政策判斷,與說研究已經消除了對那項選擇的全部問題,需要留下區別。
這樣的錯位不需要壞人。審查者認真按授權工作,採用者遵循通過即可採用的規定,答覆者依慣例將已審事項結案。每一步都有來由,最初那項問題卻可能一路沒有被處理。
若只找隱藏動機,就可能漏掉這些交接規則。有人確實可能借科學推動立場,那是另一個需要證據的機制;它可以並存,卻不是每次範圍錯位的必要條件。批評不應先要求編出一個偽裝者。
最自然的補法是擴大授權,讓證據審查也接規範問題。這可能有用,但若成員資格仍要求不得否定被問的那條前提,新增文字並沒有帶來相對於前提的獨立追問。
內部當然可能自己改寫舊做法。這個可能性不應被否認,卻也不能證明現在已有一處可以尋址、能要求回應與復審的位置。曾經發生變化,與受影響者有辦法啟動變化,需要分別說明。
真實規則可以先給範圍劃清。美國國家標準學會的標準審查委員會說明,它不評價標準內容,也不審技術問題本身的申訴;但可審技術異議是否按適當程序被考慮。這是公開的功能邊界,不是本身已經錯送的證據。
若後來有人拿程序合規結論,去宣佈技術前提的質疑已答,才需要對那次交接查記錄。原論文沒有找到這一實際結案個案,便只把它留作可能場所。不能為了一個好例子,替沒有的證據補齊最後一步。
GRADE也不能被草率拿來當反面。其2013年手冊在評證據之前,就要求先考慮哪些患者重要結局應當進入,以及重要程度;它沒有把這一取捨簡單假裝不存在。具體誰參與、有沒有足夠復審,仍需另查。
因此,一項低偏倚風險評定,是否被用來結束對研究終點選擇的質疑,要找實際援引;一篇統計分析通過審稿,是否被用來確認某閾值適用,也要找處理記錄。可能發生,不等於已經發生。
原論文還提出一條待證路徑:若結案只接收證據審查結論,而規範前提的追問又在別的有效程序中進不去,兩邊合在一起,便可能讓未經說明的取捨繼續像純技術一樣運行。
兩個條件缺一,不能把故事講滿。別處若有能接的權限,就未必是完全排除;結案若接受別種依據,也不是只能向證據證書借答覆。源文在查過的規則中,沒有找到同時滿足的實例。
這份沒有找到很重要。它既不證明錯送少見,也不證明無處不在;只說明當前材料到此。一個方法若要求別人承認證明範圍,自己便不能把有可能寫成已確立。
所以,問的對象始終很具體。哪一質疑,哪份任務,哪項授權,哪段處理,哪句限度,哪次結案。它們能幫助拆開一種穩定卻無意的誤認,也可能顯示這一回其實已經答到了。
這一篇沒有裁定某個輻射模型、統計門檻或醫學終點應該選哪一個。它保護的是不同問題仍有各自的入口:證據品質繼續認真審,取捨理由也不必靠偽裝成資料錯誤,才能進入討論。
一枚通過印章可以保留,也應該保留它真正證明的重量。旁邊還可以寫上另一項未答。讓結論回到自己的範圍,不是削弱科學,而是讓它不必替未完成的判斷出具一張已經完成的證明。
Source & reading note原论文与阅读说明原論文與閱讀說明
Ten essays draw on the Disciplines prequel and nine papers. Unattributed applicants, scores, meetings and procedural handovers are imagined. Linked texts, studies and rules retain their dates and evidential limits. The claims that divisions leave something uncontained and that people are more than tools are openly assumed philosophical and normative starting points, not empirical laws. Evidence assessment can itself consider values; professional boundaries, limited authority and reasoned retention are not failures by definition. Missing complete cases are not supplied as established findings; unverified powers are not declared absent, and an unsuccessful search establishes no frequency. These essays prescribe no diagnosis, lending cutoff or clinical action and offer no legal or professional operating advice. English is independently written.
十篇据《学科论》前置篇及九篇正文改写。窗口、评分、会议与程序交接中未另注出处的人物和场景为设想;真实文本、研究与规则另列来源,并注明材料日期和能证明的范围。划分总有未尽、以及人不只是工具,是原作公开承担的哲学与规范起点,不冒充经验定律。证据审查本身可以处理价值,专业边界、有限授权和审后保留不等于失职。原文没有查得的完整实例不补成已证事实,未核不写成不存在;没有发现实例也不据此判断发生频率。这里不决定诊断、信贷门槛或医学处置,不作法律与专业操作建议。简繁中文同文,英文独立重写。
十篇據《學科論》前置篇及九篇正文改寫。窗口、評分、會議與程序交接中未另注出處的人物和場景為設想;真實文本、研究與規則另列來源,並註明材料日期和能證明的範圍。劃分總有未盡、以及人不只是工具,是原作公開承擔的哲學與規範起點,不冒充經驗定律。證據審查本身可以處理價值,專業邊界、有限授權和審後保留不等於失職。原文沒有查得的完整實例不補成已證事實,未核不寫成不存在;沒有發現實例也不據此判斷發生頻率。這裡不決定診斷、信貸門檻或醫學處置,不作法律與專業操作建議。簡繁中文同文,英文獨立重寫。
Read the source paper ↗阅读原论文 ↗閱讀原論文 ↗
ANSI Board of Standards Review: functions and appeal scopeANSI标准审查委员会职责与申诉范围ANSI標準審查委員會職責與申訴範圍 ↗